Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.

ABSTRACT:

Purpose of review

Hypereosinophilic syndrome (HES) is characterized by persistent hypereosinophilia associated with end-organ damage. As our understanding of the pathogenesis of various forms of HES broadens, so does our ability to tailor steroid-sparing therapies for each subtype. The purpose of this review is to summarize recent literature related to the etiology, diagnosis, and management of HES.

Recent findings

Mutations involved in subsets of HES can guide the choice of tyrosine kinase inhibitors beyond just imatinib. Several biologics that target interleukin-5 or its receptor have shown beneficial and selective eosinophil-reducing effects in clinical trials for asthma and other disorders including HES. Early clinical data with emerging therapies such as dexpramipexole

SUBMITTER: Dispenza MC 

PROVIDER: S-EPMC6029712 | biostudies-literature | 2018 Jun

REPOSITORIES: biostudies-literature